Gene Fusion in Malignant Glioma: An Emerging Target for Next-Generation Personalized Treatment

Tao Xu; Hongxiang Wang; Xiaoquan Huang; Weiqing Li; Qilin Huang; Yong Yan; Juxiang Chen

doi:10.1016/j.tranon.2018.02.020

Gene Fusion in Malignant Glioma: An Emerging Target for Next-Generation Personalized Treatment

Transl Oncol. 2018 Jun;11(3):609-618. doi: 10.1016/j.tranon.2018.02.020. Epub 2018 Mar 20.

Authors

Tao Xu¹, Hongxiang Wang¹, Xiaoquan Huang², Weiqing Li³, Qilin Huang¹, Yong Yan¹, Juxiang Chen⁴

Affiliations

¹ Department of Neurosurgery, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China.
² Center of Evidence-based Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
³ Department of Pathology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China.
⁴ Department of Neurosurgery, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China. Electronic address: juxiangchen@smmu.edu.cn.

Abstract

Malignant gliomas are heterogeneous diseases in genetic basis. The development of sequencing techniques has identified many gene rearrangements encoding novel oncogenic fusions in malignant glioma to date. Understanding the gene fusions and how they regulate cellular processes in different subtypes of glioma will shed light on genomic diagnostic approaches for personalized treatment. By now, studies of gene fusions in glioma remain limited, and no medication has been approved for treating the malignancy harboring gene fusions. This review will discuss the current characterization of gene fusions occurring in both adult and pediatric malignant gliomas, their roles in oncogenesis, and the potential clinical implication as therapeutic targets.

Publication types

Review